SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.
Member of the Swiss Biotech Association
Member
SEAL Therapeutics AG
SEAL Therapeutics AG
Verified listing
-
Founded2021
-
Employees in Switzerland1-9
- Website
- Get directions
- Bookmark
- Share
- Report
- prev
- next